Wiki · UC
43 questions, drawn from this site's literature corpus. Draft pages are not yet clinician-reviewed.
What clinical parameters define steroid‑refractory ASUC draftIn patients with steroid‑refractory ASUC, how do short‑term colectomy rates compare between IV cyclosporine and infliximab as first‑line rescue therapy draftIn elderly patients (≥70 years) with steroid‑refractory ASUC and significant renal impairment, is cyclosporine or infliximab safer as rescue therapy draftIn ASUC with high stool frequency but no systemic toxicity, is immediate subtotal colectomy or awaiting response to rescue therapy preferred draftWhat is the colonic diameter threshold defining toxic megacolon in patients with ASUC draftIn patients with moderate‑to‑severe UC who have failed anti‑TNF therapy, how does risankizumab compare to vedolizumab in achieving clinical remission at 52 weeks draftIn elderly patients (≥70 years) with UC and significant comorbidities, is subtotal colectomy with end ileostomy preferable to TAC with IPAA for perioperative risk draftWhat is the evidence that subtotal colectomy with end ileostomy reduces long‑term CRC incidence in patients with UC compared with medical therapy alone draftWhat is the cumulative risk of CRC in patients with UC after 30 years of disease duration draftIn patients with UC of 15 years' duration with moderate activity and no dysplasia, is mesalamine chemoprevention or adding a thiopurine preferred for CRC risk reduction draftWhat oral mesalamine dose range is used for maintenance therapy in patients with UC in remission draftIn patients with moderately active UC not responding to mesalamine, is prednisone induction or azathioprine preferred draftIn patients with isolated HGD confined to a single colonic segment, how does the risk of progression to CRC after endoscopic mucosal resection compare with that after segmental colectomy draftDoes high‑definition white‑light colonoscopy with targeted biopsies detect dysplasia at a higher rate than conventional chromoendoscopy in patients with long‑standing UC draftIn patients with extensive UC and no prior dysplasia, is chromoendoscopy or standard white‑light colonoscopy with random biopsies preferred at the first surveillance colonoscopy draftWhat is the evidence that chromoendoscopy reduces CRC incidence in UC compared with standard surveillance protocols draftDoes laparoscopic TPC reduce postoperative morbidity compared with open TPC in patients with UC draftDoes the UCEIS provide better predictive value for clinical remission than the Mayo Endoscopic Score in patients with moderate disease draftIn patients with UC in clinical remission with a Mayo endoscopic score of 1, is intensifying immunosuppression or continuing the current maintenance regimen preferred draftWhat clinical criteria define steroid‑dependent UC draftWhat is the rate of anastomotic leak after laparoscopic total colectomy with IPAA in patients with UC draftDoes robotic‑assisted total colectomy reduce conversion to open surgery compared with conventional laparoscopic total colectomy in UC draftIn patients with UC and severe rectal dysplasia, is IPAA, IRA, or permanent ileostomy preferred to minimize cancer risk while preserving bowel function draftDoes rectal mesalamine foam achieve better mucosal healing than oral mesalamine in adolescents with mild to moderate UC draftIn adolescents newly diagnosed with extensive UC, are systemic corticosteroids or immediate biologic therapy preferred draftWhat is the evidence that early use of biologic agents improves long‑term remission rates in pediatric UC compared with a step‑up strategy draftWhat is the evidence that pregnancy increases the risk of pouchitis in patients with IPAA draftIn patients with UC, does the risk of colorectal dysplasia differ between those with and without PSC draftWhat is the evidence that ursodeoxycholic acid lowers CRC risk in patients with UC and PSC draftIn patients with UC and a symptomatic retained rectal stump, is endoscopic mucosal resection of the stump or definitive restorative proctocolectomy preferred draftIn asymptomatic patients with UC and a retained rectal stump after Hartmann, is endoscopic closure with an over-the-scope clip or leaving it open with monitoring preferred draftWhat is the risk of pouchitis after IPAA for UC draftIn patients hospitalized with ASUC, is initial treatment with infliximab or cyclosporine A preferred draftIn pediatric patients with anti-TNF-refractory UC who achieve remission on ustekinumab, does duration of remission differ between those previously treated with vedolizumab and those treated with anti-TNF alone draftIn anti‑TNF-naive adults with moderate-to-severe UC, is infliximab or adalimumab preferred for induction draftIn patients with acute steroid-refractory UC, does IV cyclosporine reduce the long-term risk of CRC compared with infliximab draftIn patients with UC treated with anti-TNF (adalimumab or infliximab), does timing of initiation relative to disease activity affect clinical remission at one year draftIn pediatric patients hospitalized for severe UC without clinical remission after 14 days of medical therapy, is colectomy or continued medical therapy preferred draftIn patients with severe medically refractory IBDU, should infliximab be considered before colectomy with IPAA, and what is the potential benefit beyond disease control draftWhich clinical and laboratory factors independently predict failure of medical therapy in patients with severe UC draftDoes oral ciprofloxacin therapy for pouchitis increase the frequency of E. coli gyrA and parC mutations associated with quinolone resistance draftIn patients with UC undergoing restorative proctectomy with ileal J-pouch anal anastomosis, should a DLI be performed to protect the anastomosis draftIn patients with quiescent IBD, how does the prevalence of ANCA (including the perinuclear subtype) compare between UC and CD draft